- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: NSC 625987 | NSC-625987 | NSC625987
Compound class: Synthetic organic
Comment: NSC 625987 was originally reported as a cyclin-dependent kinase 4 (CDK4) inhibitor, with >500-fold selectivity compared to CDK2 (IC50 >100 μM for cdc2/cyclin A, CDK2/cyclin A and CDK2/cyclin E) . However, kinase profiling results reported by Jorda et al. (2018) found that no kinases tested were >50% inhibited by 10 μM NSC 625987 . In addition, these authors found no evidence of CDK4 inhibition in cellular assays. Therefore, caution is advised when choosing CDK4 pharmacological tools.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]
2. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem. J., 451 (2): 313-28. [PMID:23398362]
3. Jorda R, Hendrychová D, Voller J, Řezníčková E, Gucký T, Kryštof V. (2018)
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?.
J. Med. Chem., 61 (20): 9105-9120. [PMID:30234987]
4. Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ. (1999)
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Clin. Cancer Res., 5 (12): 4279-86. [PMID:10632371]